AJANTPHARM:NSE Ajanta Pharma Limited

INR 1,308.25 9.45 0.727595
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Slightly Bullish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

INR 1,308.25

+9.45 (+0.73)%

INR 162.55B

0.12M

N/A

N/A

Icon

AJANTPHARM:NSE

Ajanta Pharma Limited (INR)
COMMON STOCK | NSE
INR 1,308.25
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Slightly Bullish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

INR 162.55B

N/A

INR 1,308.25

Ajanta Pharma Limited Stock Forecast

Show ratings and price targets of :
INR 1,465.00
(+11.98%)

Based on the Ajanta Pharma Limited stock forecast from 3 analysts, the average analyst target price for Ajanta Pharma Limited is INR 1,465.00 over the next 12 months. Ajanta Pharma Limited’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Ajanta Pharma Limited is Slightly Bullish , which is based on 9 positive signals and 5 negative signals. At the last closing, Ajanta Pharma Limited’s stock price was INR 1,308.25. Ajanta Pharma Limited’s stock price has changed by +0.65% over the past week, -0.33% over the past month and +14.56% over the last year.

No recent analyst target price found for Ajanta Pharma Limited
No recent average analyst rating found for Ajanta Pharma Limited

Company Overview

Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets finished dosages. The company markets and serves various therapeutic segments, such as anti-biotic, anti-malarial, anti-diabetic, cardiology,...Read More

Ajanta House, Mumbai, India, 400067

N/A

March

INR

India

Adjusted Closing Price

Loading...

Technical Indicators

Unadjusted Closing Price

Loading...

Assets

Top Holdings

Top Sectors

Top Regions

Share Volume

Loading...

Relative Performance

Symbol Capital Gain Dividend Return Total Return
Loading...

Stocks Similar To Ajanta Pharma Limited (Sector: Drug Manufacturers-Specialty & Generic )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SUNPHARMA:NSE
Sun Pharmaceutical Industries .. +15.75 (+1.64%) INR2,327.11B 55.55 30.46

ETFs Containing AJANTPHARM

Symbol Name AJANTPHARM's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About AJANTPHARM:NSE Stock

Based on ratings from 3 analysts Ajanta Pharma Limited's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 5 buy, sell and hold ratings.

AJANTPHARM:NSE stock's dividend yield is 0.54%. Our analysis grades AJANTPHARM:NSE stock's dividend yield at F. This means that AJANTPHARM:NSE stock's dividend yield is above 33% of the stocks in the Drug Manufacturers-Specialty & Generic sector in the NSE exchange. Based on this AJANTPHARM:NSE may be a poor dividend stock for its sector.

Based on targets from 3 analysts, the average taret price for AJANTPHARM:NSE is INR 1,465.00 over the next 12 months. The maximum analyst target price is INR 1520 while the minimum anlayst target price is INR 1385.

AJANTPHARM:NSE stock's Price/Earning ratio is 27.89. Our analysis grades AJANTPHARM:NSE stock's Price / Earning ratio at F. This means that AJANTPHARM:NSE stock's Price/Earning ratio is above 53% of the stocks in the Drug Manufacturers-Specialty & Generic sector in the NSE exchange. Based on this AJANTPHARM:NSE may be a overvalued for its sector.

The last closing price of AJANTPHARM:NSE's stock was INR 1,308.25.

The most recent market capitalization for AJANTPHARM:NSE is INR 162.55B.

Based on targets from 3 analysts, the average taret price for AJANTPHARM:NSE is projected at INR 1,465.00 over the next 12 months. This means that AJANTPHARM:NSE's stock price may go up by +11.98% over the next 12 months.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...